The MEQ is a self-report measure that provides insight into a key aspect of the psychedelic experience.
This study is the first of its kind to suggest that psilocybin enhances emotional empathy but does not affect moral behavior.
Researchers at the forefront of psychedelic science put forth their arguments in this important debate.
Changes in brain functioning, new synthesis methods, and psychotherapy dominate this year’s most-cited psilocybin papers.
This study provides meaningful access to some lesser-known magic mushroom compounds and conducts biological testing on them for the first time.
Interestingly, changes in migraine frequency were not correlated with the intensity of the acute psychotropic effects.
This influential study advances the understanding of magic mushroom physiology and helps answer several fundamental questions.
A recent study shows DMT reduces the cellular stress caused by a stroke and speeds up recovery time in rats. These findings highlight the expanding therapeutic potential of DMT regarding neurological disorders.
Brain imaging research reveals where psychedelic compounds such as psilocybin and LSD manifest their effects.
There is much research into psychedelic treatment of mental disorders, but psychedelics might be effective in treating autoimmune disorders as well.